Nubeqa

Active substance

darolutamide

Holder

Bayer SA-NV

Status

Running

Indication

treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with ADT and docetaxel.

Public documents

Approbation

Information for the patient

Informed consent

Last update

28/09/2022